Jimbo
New Member
In February 2007, DEA Administrative Law Judge Mary Bittner recommended that Professor Lyle Craker and the University of Massachusetts be granted a license to produce research-grade marijuana for FDA-and DEA-approved clinical studies of medical marijuana. The DEA has ignored her recommendation and continued to block research.
The DEA's attempt to bury the university's application is hypocritical, since the DEA continually cites insufficient research as a reason for keeping marijuana off the controlled market ... while simultaneously blocking the very research needed to take preliminary steps towards FDA approval.
Please take one minute to ask your member of Congress to sign on to Rep. John Oliver (D-Mass.) and Rep. Dana Rohrabacher's (R-Calif.) letter to the DEA.
https://secure2.convio.net/mpp/site/Advocacy?cmd=display&page=UserAction&id=119
Send this letter in;^
Would you please sign on to Sen. Ted Kennedy and Sen. John Kerry's letter to the DEA in support of Professor Lyle Craker's application for a license to produce research-grade marijuana for FDA- and DEA-approved clinical studies of medical marijuana at the University of Massachusetts?
Marijuana is currently the only medical drug in our pharmacopoeia for which the federal government has a monopoly on production. Not only does this policy prevent researchers like Professor Craker from conducting research, a necessary first step toward FDA clinical trials, but it also keeps U.S. businesses from entering the cannabinoid drug market.
Other countries are already capitalizing on the lucrative and promising cannabinoid drug market. GW Pharmaceuticals, a pharmaceutical company based in England, has teamed up with Otsuka, a Japanese company, to conduct trials for a marijuana-based drug, Sativex. Since the U.S. government's monopoly on marijuana is keeping our pharmaceutical industry from competing with companies overseas, these companies have an edge in the marketplace.
It's time to put medical marijuana through FDA clinical trials and allow for research and drug production by American pharmaceutical companies.
Please support American industry and sound drug policy by signing on to Sen. Kennedy and Sen. Kerry's letter.
The DEA's attempt to bury the university's application is hypocritical, since the DEA continually cites insufficient research as a reason for keeping marijuana off the controlled market ... while simultaneously blocking the very research needed to take preliminary steps towards FDA approval.
Please take one minute to ask your member of Congress to sign on to Rep. John Oliver (D-Mass.) and Rep. Dana Rohrabacher's (R-Calif.) letter to the DEA.
https://secure2.convio.net/mpp/site/Advocacy?cmd=display&page=UserAction&id=119
Send this letter in;^
Would you please sign on to Sen. Ted Kennedy and Sen. John Kerry's letter to the DEA in support of Professor Lyle Craker's application for a license to produce research-grade marijuana for FDA- and DEA-approved clinical studies of medical marijuana at the University of Massachusetts?
Marijuana is currently the only medical drug in our pharmacopoeia for which the federal government has a monopoly on production. Not only does this policy prevent researchers like Professor Craker from conducting research, a necessary first step toward FDA clinical trials, but it also keeps U.S. businesses from entering the cannabinoid drug market.
Other countries are already capitalizing on the lucrative and promising cannabinoid drug market. GW Pharmaceuticals, a pharmaceutical company based in England, has teamed up with Otsuka, a Japanese company, to conduct trials for a marijuana-based drug, Sativex. Since the U.S. government's monopoly on marijuana is keeping our pharmaceutical industry from competing with companies overseas, these companies have an edge in the marketplace.
It's time to put medical marijuana through FDA clinical trials and allow for research and drug production by American pharmaceutical companies.
Please support American industry and sound drug policy by signing on to Sen. Kennedy and Sen. Kerry's letter.
